Latest Hotspot

Neurocrine Initiates Phase I Trial of VMAT2 Inhibitor NBI-1065890

2 April 2024
2 min read

Neurocrine Biosciences, Inc. has launched a Phase 1 clinical trial to examine the safety profile, acceptability, absorption, distribution, and effect mechanisms of the trial drug NBI-1065890 in a group of healthy adults. The substance NBI-1065890 under examination is a targeted oral therapy that acts as a selective blocker of VMAT2, and it may offer therapeutic benefits for a range of neurologic and mental health disorders.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Neurocrine Biosciences possesses profound expertise and a track record in the realm of VMAT2 inhibition, as indicated by the creation and progression of valbenazine as a remedy for the involuntary movements related to tardive dyskinesia as well as Huntington’s disease-associated chorea, declared Eiry W. Roberts, Chief Medical Officer at the organization. 

Dr. Roberts further articulated enthusiasm for the advancement of a novel, proprietary, excessively active, and orally administered selective VMAT2 inhibitor to clinical trials, with aspirations to offer a unique therapeutic option for various neurological and psychiatric disorders.

Compounds that impede VMAT2 have been demonstrated in clinical settings to be efficacious in managing disorders characterized by excessive motor activity, and are significant in the presynaptic regulation of dopamine. In 2017, Neurocrine successfully gained authorization from the U.S. Food and Drug Administration for valbenazine as the premier medication fashioned specifically for the management of tardive dyskinesia, substantiating the company’s leadership in selective VMAT2 inhibition. Furthering its achievements, the firm acquired FDA endorsement for valbenazine to address chorea manifestations of Huntington’s disease in 2023.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 文本, 应用程序, 表格

描述已自动生成

According to the data provided by the Synapse Database, As of April 1, 2024, there are 29 investigational drugs for the VMAT2 target, including 24 indications, 62 R&D institutions involved, with related clinical trials reaching 104, and as many as 1654 patents.

NBI-1065890 targets VMAT2 and is being developed for the treatment of schizophrenia. Currently in Phase 1, this drug holds promise for potentially addressing the unmet medical needs of patients with this debilitating mental diseases.

图形用户界面, 文本, 应用程序

描述已自动生成

Relaxin Receptors: Therapeutic Opportunity for Heart Failure and Pulmonary Arterial Hypertension
Hot Spotlight
5 min read
Relaxin Receptors: Therapeutic Opportunity for Heart Failure and Pulmonary Arterial Hypertension
2 April 2024
Advancing GPCR-Targeted Therapy: Tectonic Therapeutics' GEODe Platform Overcomes Discovery Challenges.
Read →
Gilead-Xilio Ink Deal on IL-12 Oncology Project
Latest Hotspot
3 min read
Gilead-Xilio Ink Deal on IL-12 Oncology Project
2 April 2024
Gilead and Xilio have entered into a unique licensing deal dedicated to the development of an oncology-targeted IL-12 initiative.
Read →
What is Drug Delivery System?
"What" Series
2 min read
What is Drug Delivery System?
2 April 2024
A drug delivery system is a method or technology used to transport a pharmaceutical compound into the body to achieve a therapeutic effect.
Read →
Ironwood Pharma's Phase 2 STARGAZE Study Shows Promise for Apraglutide in Treatment-Resistant GI aGVHD
Latest Hotspot
3 min read
Ironwood Pharma's Phase 2 STARGAZE Study Shows Promise for Apraglutide in Treatment-Resistant GI aGVHD
2 April 2024
Ironwood Pharma Reveals Encouraging Outcomes in Phase 2 STARGAZE Study for Apraglutide Treating GI aGVHD Unresponsive to Steroids.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.